The city of Stanford, California, currently has 15 active clinical trials seeking participants for Breast Cancer research studies.
Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)
NCT05259696
Recruiting
This is a Phase 1/2, first-in-human, open-label, dose escalation and dose-expansion study of E-602, administered alone and in combination with cemiplimab.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/22/2023
Locations: Stanford Health Care, Stanford, California
Conditions: Oncology, Melanoma, Ovarian Cancer, NSCLC, Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Cancer, CRC, Colon Cancer, Breast Cancer, Gastric Cancer, EGJ, Esophagogastric Junction Cancer, Head and Neck Cancer, Urothelial Cancer, Bladder Cancer
Register for Updates
A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer
NCT05966584
Recruiting
The researcher are doing this study to find out whether benralizumab is effective at preventing skin rashes caused by alpelisib in people who have metastatic breast cancer. Skin rash is a common side effect of alpelisib. Researchers think adding benralizumab to the standard-of-care hormone treatment and alpelisib may prevent the patient from getting a rash.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/21/2023
Locations: Stanford University, Stanford, California
Conditions: Breast Cancer
Register for Updates
Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer
NCT04756765
Recruiting
This purpose of this study is to test if talazoparib is safe and evaluate its response to advanced breast cancer associated with mutation of gene called PALB.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/23/2023
Locations: Stanford University, Stanford, California
Conditions: Breast Cancer, Advanced Breast Cancer
Register for Updates